nodes	percent_of_prediction	percent_of_DWPC	metapath
Emedastine—Keratitis—Erlotinib—kidney cancer	0.0258	0.0258	CcSEcCtD
Emedastine—Eye pruritus—Paclitaxel—kidney cancer	0.0218	0.0218	CcSEcCtD
Emedastine—Lacrimation increased—Sunitinib—kidney cancer	0.0157	0.0157	CcSEcCtD
Emedastine—Dry eye—Erlotinib—kidney cancer	0.0155	0.0155	CcSEcCtD
Emedastine—Keratitis—Paclitaxel—kidney cancer	0.015	0.015	CcSEcCtD
Emedastine—Keratitis—Capecitabine—kidney cancer	0.0123	0.0123	CcSEcCtD
Emedastine—Sinusitis—Temsirolimus—kidney cancer	0.0123	0.0123	CcSEcCtD
Emedastine—Rhinitis—Temsirolimus—kidney cancer	0.0118	0.0118	CcSEcCtD
Emedastine—Eye irritation—Paclitaxel—kidney cancer	0.0114	0.0114	CcSEcCtD
Emedastine—Eye disorder—Temsirolimus—kidney cancer	0.011	0.011	CcSEcCtD
Emedastine—Cardiac disorder—Temsirolimus—kidney cancer	0.0109	0.0109	CcSEcCtD
Emedastine—Lacrimation increased—Paclitaxel—kidney cancer	0.0106	0.0106	CcSEcCtD
Emedastine—Eye disorder—Pazopanib—kidney cancer	0.0103	0.0103	CcSEcCtD
Emedastine—Mental disorder—Temsirolimus—kidney cancer	0.0103	0.0103	CcSEcCtD
Emedastine—Cardiac disorder—Pazopanib—kidney cancer	0.0103	0.0103	CcSEcCtD
Emedastine—Dysgeusia—Temsirolimus—kidney cancer	0.01	0.01	CcSEcCtD
Emedastine—Mental disorder—Pazopanib—kidney cancer	0.00968	0.00968	CcSEcCtD
Emedastine—Dysgeusia—Pazopanib—kidney cancer	0.00942	0.00942	CcSEcCtD
Emedastine—Eye irritation—Capecitabine—kidney cancer	0.00937	0.00937	CcSEcCtD
Emedastine—Sinusitis—Everolimus—kidney cancer	0.00912	0.00912	CcSEcCtD
Emedastine—Vision blurred—Pazopanib—kidney cancer	0.00906	0.00906	CcSEcCtD
Emedastine—Dry eye—Paclitaxel—kidney cancer	0.009	0.009	CcSEcCtD
Emedastine—Lacrimation—Doxorubicin—kidney cancer	0.00877	0.00877	CcSEcCtD
Emedastine—Rhinitis—Everolimus—kidney cancer	0.00875	0.00875	CcSEcCtD
Emedastine—Lacrimation increased—Capecitabine—kidney cancer	0.00868	0.00868	CcSEcCtD
Emedastine—Unspecified disorder of skin and subcutaneous tissue—Temsirolimus—kidney cancer	0.00863	0.00863	CcSEcCtD
Emedastine—Nervous system disorder—Temsirolimus—kidney cancer	0.00817	0.00817	CcSEcCtD
Emedastine—Eye disorder—Everolimus—kidney cancer	0.00815	0.00815	CcSEcCtD
Emedastine—Unspecified disorder of skin and subcutaneous tissue—Pazopanib—kidney cancer	0.00813	0.00813	CcSEcCtD
Emedastine—Cardiac disorder—Everolimus—kidney cancer	0.0081	0.0081	CcSEcCtD
Emedastine—Skin disorder—Temsirolimus—kidney cancer	0.00809	0.00809	CcSEcCtD
Emedastine—Keratitis—Doxorubicin—kidney cancer	0.00795	0.00795	CcSEcCtD
Emedastine—Eye disorder—Erlotinib—kidney cancer	0.00787	0.00787	CcSEcCtD
Emedastine—Eye pain—Paclitaxel—kidney cancer	0.00784	0.00784	CcSEcCtD
Emedastine—Nervous system disorder—Pazopanib—kidney cancer	0.0077	0.0077	CcSEcCtD
Emedastine—Mental disorder—Everolimus—kidney cancer	0.00764	0.00764	CcSEcCtD
Emedastine—Skin disorder—Pazopanib—kidney cancer	0.00762	0.00762	CcSEcCtD
Emedastine—Dysgeusia—Everolimus—kidney cancer	0.00744	0.00744	CcSEcCtD
Emedastine—Dry eye—Capecitabine—kidney cancer	0.00739	0.00739	CcSEcCtD
Emedastine—Mental disorder—Erlotinib—kidney cancer	0.00737	0.00737	CcSEcCtD
Emedastine—Vision blurred—Everolimus—kidney cancer	0.00716	0.00716	CcSEcCtD
Emedastine—Pain—Temsirolimus—kidney cancer	0.00713	0.00713	CcSEcCtD
Emedastine—Cardiac disorder—Sorafenib—kidney cancer	0.00703	0.00703	CcSEcCtD
Emedastine—Eye disorder—Sunitinib—kidney cancer	0.00681	0.00681	CcSEcCtD
Emedastine—Cardiac disorder—Sunitinib—kidney cancer	0.00676	0.00676	CcSEcCtD
Emedastine—Pain—Pazopanib—kidney cancer	0.00671	0.00671	CcSEcCtD
Emedastine—Mental disorder—Sorafenib—kidney cancer	0.00663	0.00663	CcSEcCtD
Emedastine—Dysgeusia—Sorafenib—kidney cancer	0.00646	0.00646	CcSEcCtD
Emedastine—Eye pain—Capecitabine—kidney cancer	0.00643	0.00643	CcSEcCtD
Emedastine—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.00642	0.00642	CcSEcCtD
Emedastine—Discomfort—Vinblastine—kidney cancer	0.00641	0.00641	CcSEcCtD
Emedastine—Discomfort—Everolimus—kidney cancer	0.00639	0.00639	CcSEcCtD
Emedastine—Mental disorder—Sunitinib—kidney cancer	0.00638	0.00638	CcSEcCtD
Emedastine—Stinging—Doxorubicin—kidney cancer	0.00636	0.00636	CcSEcCtD
Emedastine—Dysgeusia—Sunitinib—kidney cancer	0.00621	0.00621	CcSEcCtD
Emedastine—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.0062	0.0062	CcSEcCtD
Emedastine—Nervous system disorder—Everolimus—kidney cancer	0.00608	0.00608	CcSEcCtD
Emedastine—Tachycardia—Everolimus—kidney cancer	0.00605	0.00605	CcSEcCtD
Emedastine—Skin disorder—Everolimus—kidney cancer	0.00602	0.00602	CcSEcCtD
Emedastine—Asthenia—Temsirolimus—kidney cancer	0.00598	0.00598	CcSEcCtD
Emedastine—Pruritus—Temsirolimus—kidney cancer	0.00589	0.00589	CcSEcCtD
Emedastine—Nervous system disorder—Erlotinib—kidney cancer	0.00586	0.00586	CcSEcCtD
Emedastine—Rhinitis—Gemcitabine—kidney cancer	0.00586	0.00586	CcSEcCtD
Emedastine—Skin disorder—Erlotinib—kidney cancer	0.00581	0.00581	CcSEcCtD
Emedastine—Cardiac disorder—Vincristine—kidney cancer	0.00572	0.00572	CcSEcCtD
Emedastine—Asthenia—Pazopanib—kidney cancer	0.00563	0.00563	CcSEcCtD
Emedastine—Lacrimation increased—Doxorubicin—kidney cancer	0.0056	0.0056	CcSEcCtD
Emedastine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.00557	0.00557	CcSEcCtD
Emedastine—Pruritus—Pazopanib—kidney cancer	0.00555	0.00555	CcSEcCtD
Emedastine—Cardiac disorder—Gemcitabine—kidney cancer	0.00543	0.00543	CcSEcCtD
Emedastine—Mental disorder—Vincristine—kidney cancer	0.0054	0.0054	CcSEcCtD
Emedastine—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.00536	0.00536	CcSEcCtD
Emedastine—Pain—Vinblastine—kidney cancer	0.00532	0.00532	CcSEcCtD
Emedastine—Pain—Everolimus—kidney cancer	0.0053	0.0053	CcSEcCtD
Emedastine—Nervous system disorder—Sorafenib—kidney cancer	0.00528	0.00528	CcSEcCtD
Emedastine—Rash—Temsirolimus—kidney cancer	0.00525	0.00525	CcSEcCtD
Emedastine—Dermatitis—Temsirolimus—kidney cancer	0.00525	0.00525	CcSEcCtD
Emedastine—Skin disorder—Sorafenib—kidney cancer	0.00523	0.00523	CcSEcCtD
Emedastine—Headache—Temsirolimus—kidney cancer	0.00522	0.00522	CcSEcCtD
Emedastine—Sinusitis—Paclitaxel—kidney cancer	0.00512	0.00512	CcSEcCtD
Emedastine—Pain—Erlotinib—kidney cancer	0.00511	0.00511	CcSEcCtD
Emedastine—Abnormal dreams—Doxorubicin—kidney cancer	0.0051	0.0051	CcSEcCtD
Emedastine—Nervous system disorder—Sunitinib—kidney cancer	0.00508	0.00508	CcSEcCtD
Emedastine—Discomfort—Dactinomycin—kidney cancer	0.00505	0.00505	CcSEcCtD
Emedastine—Skin disorder—Sunitinib—kidney cancer	0.00503	0.00503	CcSEcCtD
Emedastine—Rash—Pazopanib—kidney cancer	0.00495	0.00495	CcSEcCtD
Emedastine—Dermatitis—Pazopanib—kidney cancer	0.00494	0.00494	CcSEcCtD
Emedastine—Headache—Pazopanib—kidney cancer	0.00492	0.00492	CcSEcCtD
Emedastine—Rhinitis—Paclitaxel—kidney cancer	0.00491	0.00491	CcSEcCtD
Emedastine—Dry eye—Doxorubicin—kidney cancer	0.00476	0.00476	CcSEcCtD
Emedastine—Pain—Sorafenib—kidney cancer	0.0046	0.0046	CcSEcCtD
Emedastine—Eye disorder—Paclitaxel—kidney cancer	0.00457	0.00457	CcSEcCtD
Emedastine—Cardiac disorder—Paclitaxel—kidney cancer	0.00454	0.00454	CcSEcCtD
Emedastine—Asthenia—Vinblastine—kidney cancer	0.00446	0.00446	CcSEcCtD
Emedastine—Asthenia—Everolimus—kidney cancer	0.00445	0.00445	CcSEcCtD
Emedastine—Pain—Sunitinib—kidney cancer	0.00443	0.00443	CcSEcCtD
Emedastine—Pruritus—Everolimus—kidney cancer	0.00438	0.00438	CcSEcCtD
Emedastine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.0043	0.0043	CcSEcCtD
Emedastine—Nervous system disorder—Vincristine—kidney cancer	0.00429	0.00429	CcSEcCtD
Emedastine—Asthenia—Erlotinib—kidney cancer	0.00429	0.00429	CcSEcCtD
Emedastine—Mental disorder—Paclitaxel—kidney cancer	0.00429	0.00429	CcSEcCtD
Emedastine—Discomfort—Gemcitabine—kidney cancer	0.00428	0.00428	CcSEcCtD
Emedastine—Pruritus—Erlotinib—kidney cancer	0.00423	0.00423	CcSEcCtD
Emedastine—Pain—Dactinomycin—kidney cancer	0.00419	0.00419	CcSEcCtD
Emedastine—Dysgeusia—Paclitaxel—kidney cancer	0.00417	0.00417	CcSEcCtD
Emedastine—Eye pain—Doxorubicin—kidney cancer	0.00415	0.00415	CcSEcCtD
Emedastine—Nervous system disorder—Gemcitabine—kidney cancer	0.00407	0.00407	CcSEcCtD
Emedastine—Skin disorder—Gemcitabine—kidney cancer	0.00403	0.00403	CcSEcCtD
Emedastine—Rhinitis—Capecitabine—kidney cancer	0.00403	0.00403	CcSEcCtD
Emedastine—Vision blurred—Paclitaxel—kidney cancer	0.00402	0.00402	CcSEcCtD
Emedastine—Rash—Everolimus—kidney cancer	0.00391	0.00391	CcSEcCtD
Emedastine—Dermatitis—Everolimus—kidney cancer	0.0039	0.0039	CcSEcCtD
Emedastine—Headache—Vinblastine—kidney cancer	0.0039	0.0039	CcSEcCtD
Emedastine—Headache—Everolimus—kidney cancer	0.00388	0.00388	CcSEcCtD
Emedastine—Asthenia—Sorafenib—kidney cancer	0.00386	0.00386	CcSEcCtD
Emedastine—Pruritus—Sorafenib—kidney cancer	0.00381	0.00381	CcSEcCtD
Emedastine—Rash—Erlotinib—kidney cancer	0.00377	0.00377	CcSEcCtD
Emedastine—Dermatitis—Erlotinib—kidney cancer	0.00377	0.00377	CcSEcCtD
Emedastine—Eye disorder—Capecitabine—kidney cancer	0.00375	0.00375	CcSEcCtD
Emedastine—Headache—Erlotinib—kidney cancer	0.00375	0.00375	CcSEcCtD
Emedastine—Pain—Vincristine—kidney cancer	0.00374	0.00374	CcSEcCtD
Emedastine—Cardiac disorder—Capecitabine—kidney cancer	0.00373	0.00373	CcSEcCtD
Emedastine—Asthenia—Sunitinib—kidney cancer	0.00371	0.00371	CcSEcCtD
Emedastine—Pruritus—Sunitinib—kidney cancer	0.00366	0.00366	CcSEcCtD
Emedastine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.0036	0.0036	CcSEcCtD
Emedastine—Discomfort—Paclitaxel—kidney cancer	0.00358	0.00358	CcSEcCtD
Emedastine—Pain—Gemcitabine—kidney cancer	0.00355	0.00355	CcSEcCtD
Emedastine—Mental disorder—Capecitabine—kidney cancer	0.00352	0.00352	CcSEcCtD
Emedastine—Asthenia—Dactinomycin—kidney cancer	0.00352	0.00352	CcSEcCtD
Emedastine—Dysgeusia—Capecitabine—kidney cancer	0.00342	0.00342	CcSEcCtD
Emedastine—Nervous system disorder—Paclitaxel—kidney cancer	0.00341	0.00341	CcSEcCtD
Emedastine—Tachycardia—Paclitaxel—kidney cancer	0.00339	0.00339	CcSEcCtD
Emedastine—Rash—Sorafenib—kidney cancer	0.00339	0.00339	CcSEcCtD
Emedastine—Dermatitis—Sorafenib—kidney cancer	0.00339	0.00339	CcSEcCtD
Emedastine—Skin disorder—Paclitaxel—kidney cancer	0.00338	0.00338	CcSEcCtD
Emedastine—Headache—Sorafenib—kidney cancer	0.00337	0.00337	CcSEcCtD
Emedastine—Vision blurred—Capecitabine—kidney cancer	0.0033	0.0033	CcSEcCtD
Emedastine—Rash—Sunitinib—kidney cancer	0.00326	0.00326	CcSEcCtD
Emedastine—Dermatitis—Sunitinib—kidney cancer	0.00326	0.00326	CcSEcCtD
Emedastine—Headache—Sunitinib—kidney cancer	0.00324	0.00324	CcSEcCtD
Emedastine—Asthenia—Vincristine—kidney cancer	0.00314	0.00314	CcSEcCtD
Emedastine—Rash—Dactinomycin—kidney cancer	0.00309	0.00309	CcSEcCtD
Emedastine—Asthenia—Gemcitabine—kidney cancer	0.00298	0.00298	CcSEcCtD
Emedastine—Pain—Paclitaxel—kidney cancer	0.00297	0.00297	CcSEcCtD
Emedastine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.00296	0.00296	CcSEcCtD
Emedastine—Discomfort—Capecitabine—kidney cancer	0.00294	0.00294	CcSEcCtD
Emedastine—Pruritus—Gemcitabine—kidney cancer	0.00294	0.00294	CcSEcCtD
Emedastine—Nervous system disorder—Capecitabine—kidney cancer	0.0028	0.0028	CcSEcCtD
Emedastine—Tachycardia—Capecitabine—kidney cancer	0.00279	0.00279	CcSEcCtD
Emedastine—Skin disorder—Capecitabine—kidney cancer	0.00277	0.00277	CcSEcCtD
Emedastine—Rash—Vincristine—kidney cancer	0.00276	0.00276	CcSEcCtD
Emedastine—Dermatitis—Vincristine—kidney cancer	0.00276	0.00276	CcSEcCtD
Emedastine—Headache—Vincristine—kidney cancer	0.00274	0.00274	CcSEcCtD
Emedastine—Sinusitis—Doxorubicin—kidney cancer	0.00271	0.00271	CcSEcCtD
Emedastine—Rash—Gemcitabine—kidney cancer	0.00262	0.00262	CcSEcCtD
Emedastine—Dermatitis—Gemcitabine—kidney cancer	0.00262	0.00262	CcSEcCtD
Emedastine—Headache—Gemcitabine—kidney cancer	0.0026	0.0026	CcSEcCtD
Emedastine—Rhinitis—Doxorubicin—kidney cancer	0.0026	0.0026	CcSEcCtD
Emedastine—Asthenia—Paclitaxel—kidney cancer	0.0025	0.0025	CcSEcCtD
Emedastine—Pruritus—Paclitaxel—kidney cancer	0.00246	0.00246	CcSEcCtD
Emedastine—Pain—Capecitabine—kidney cancer	0.00244	0.00244	CcSEcCtD
Emedastine—Eye disorder—Doxorubicin—kidney cancer	0.00242	0.00242	CcSEcCtD
Emedastine—Cardiac disorder—Doxorubicin—kidney cancer	0.0024	0.0024	CcSEcCtD
Emedastine—Mental disorder—Doxorubicin—kidney cancer	0.00227	0.00227	CcSEcCtD
Emedastine—Dysgeusia—Doxorubicin—kidney cancer	0.00221	0.00221	CcSEcCtD
Emedastine—Rash—Paclitaxel—kidney cancer	0.00219	0.00219	CcSEcCtD
Emedastine—Dermatitis—Paclitaxel—kidney cancer	0.00219	0.00219	CcSEcCtD
Emedastine—Headache—Paclitaxel—kidney cancer	0.00218	0.00218	CcSEcCtD
Emedastine—Vision blurred—Doxorubicin—kidney cancer	0.00212	0.00212	CcSEcCtD
Emedastine—Asthenia—Capecitabine—kidney cancer	0.00205	0.00205	CcSEcCtD
Emedastine—Pruritus—Capecitabine—kidney cancer	0.00202	0.00202	CcSEcCtD
Emedastine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.00191	0.00191	CcSEcCtD
Emedastine—Discomfort—Doxorubicin—kidney cancer	0.0019	0.0019	CcSEcCtD
Emedastine—Nervous system disorder—Doxorubicin—kidney cancer	0.0018	0.0018	CcSEcCtD
Emedastine—Rash—Capecitabine—kidney cancer	0.0018	0.0018	CcSEcCtD
Emedastine—Dermatitis—Capecitabine—kidney cancer	0.0018	0.0018	CcSEcCtD
Emedastine—Tachycardia—Doxorubicin—kidney cancer	0.0018	0.0018	CcSEcCtD
Emedastine—Headache—Capecitabine—kidney cancer	0.00179	0.00179	CcSEcCtD
Emedastine—Skin disorder—Doxorubicin—kidney cancer	0.00179	0.00179	CcSEcCtD
Emedastine—Pain—Doxorubicin—kidney cancer	0.00157	0.00157	CcSEcCtD
Emedastine—Asthenia—Doxorubicin—kidney cancer	0.00132	0.00132	CcSEcCtD
Emedastine—Pruritus—Doxorubicin—kidney cancer	0.0013	0.0013	CcSEcCtD
Emedastine—Rash—Doxorubicin—kidney cancer	0.00116	0.00116	CcSEcCtD
Emedastine—Dermatitis—Doxorubicin—kidney cancer	0.00116	0.00116	CcSEcCtD
Emedastine—Headache—Doxorubicin—kidney cancer	0.00115	0.00115	CcSEcCtD
